Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07204275
Recruiting Phase 2/3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275 · tracked via the Priya Life Science Japan tracker
Sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2/3
Started
2025-09-30
Last updated
2026-09-18

Condition(s) studied

Primary Membranous Nephropathy

Investigational drug(s) / intervention(s)

Povetacicept →Tacrolimus →

Povetacicept: Solution for Subcutaneous Injection.

Tacrolimus: Capsules for Oral Administration.

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Key Inclusion Criteria: • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility Key Exclusion Criteria: • Hypersensitivity to investigational medicinal product or to any of its excipients Other protocol defined Inclusion/Exclusion criteria will apply

Primary outcome measure(s)

  • Proportion of Participants with Complete Clinical Remission Definition 1 (CR1) — At Week 104

Trial sites (115)

FacilityCityRegionStatus
Renal Associates Montgomery Alabama Recruiting
Southwest Kidney Institute, PLC (SKI) - Surprise Surprise Arizona Recruiting
Academic Medical Research Institute (AMRI) Los Angeles California Recruiting
Kaiser Permanente Sacramento Medical Center Sacramento California Recruiting
Valiance Clinical Research - Internal Medicine Tarzana California Recruiting
Western Nephrology & Metabolic Bone Disease PC Arvada Colorado Recruiting
Bioresearch Partner Miami Florida Recruiting
CTR Oakwater, LLC Orlando Florida Recruiting
Clinical Site Partners, LLC - Orlando Winter Park Florida Recruiting
DaVita Clinical Research Columbus Columbus Georgia Recruiting
Georgia Nephrology Lawrenceville Georgia Recruiting
CARE Institute-Boise Kidney Boise Idaho Recruiting
NANI Research Hinsdale Illinois Recruiting
Nephrology Associates of Northern Illinois and Indiana (NANI) - Indianapolis South Indianapolis Indiana Recruiting
Northwest Louisiana Nephrology, LLC - Shreveport Shreveport Louisiana Recruiting
DaVita Clinical Research Edina Edina Minnesota Recruiting
St. Clair Nephrology Research Roseville Missouri Recruiting
Kidney Specialists of Southern Nevada Las Vegas Nevada Recruiting
NYU Medical Center New York New York Recruiting
Carolina Nephrology Greenville Greenville South Carolina Recruiting
Carolina Nephrology, PA Spartanburg South Carolina Recruiting
El Paso Kidney Specialists El Paso Texas Recruiting
Provecta Research Network Houston Texas Recruiting
DaVita Clinical Research Houston Houston Texas Recruiting
Davita Clinical Research San Antonio San Antonio Texas Recruiting
Utah Kidney Research Salt Lake City Utah Recruiting
Milwaukee Neprologists, SC Wauwatosa Wisconsin Recruiting
Monash Medical Centre Clayton Australia Recruiting
Concord Repatriation General Hospital Concord Australia Recruiting
St George Private Hospital Kogarah Australia Recruiting
University of Newcastle - John Hunter Hospital (JHH) New Lambton Heights Australia Recruiting
Freire Pesquisa Clinica Belo Horizonte Brazil Recruiting
Santa Casa de Misericordia Porto Alegre Brazil Recruiting
Universidade Federal de Pernmabuco Recife Brazil Recruiting
Fundação Bahiana de Infectologia Salvador Brazil Recruiting
Hospital das Clinicas da Faculdade de Medicina da USP - HC- FMUSP São Paulo Brazil Recruiting
The First Affiliated Hospital of Baotou Medical College Baotou China Recruiting
Beijing Tsinghua Changgung Hospital Beijing China Recruiting
Peking University First Hospital Beijing China Recruiting
The First Affiliated Hospital of Bengbu Medical University Bengbu China Recruiting

+ 75 more sites — see the full list on the official registry below.

Other trials for the same condition

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07204275 on ClinicalTrials.gov ↗ ← All trials in Japan